Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected] Learn more

pSIRV-NF-kB-eGFP
(Plasmid #118093)

Ordering

Item Catalog # Description Quantity Price (USD)
Plasmid 118093 Standard format: Plasmid sent in bacteria as agar stab 1 $75

This material is available to academics and nonprofits only.

Backbone

  • Vector backbone
    pSIRV
  • Backbone size w/o insert (bp) 4865
  • Total vector size (bp) 5585
  • Vector type
    Retroviral

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    High Copy

Gene/Insert

  • Gene/Insert name
    eGFP
  • Species
    Synthetic
  • Insert Size (bp)
    720
  • Promoter minimal promoter with NF-kB responsive element

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site none (unknown if destroyed)
  • 3′ cloning site Not I (not destroyed)
  • 5′ sequencing primer GAGGGTATATAATGGAAGCTCG
  • (Common Sequencing Primers)

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pSIRV-NF-kB-eGFP was a gift from Peter Steinberger (Addgene plasmid # 118093 ; http://n2t.net/addgene:118093 ; RRID:Addgene_118093)
  • For your References section:

    A cellular platform for the evaluation of immune checkpoint molecules. Jutz S, Hennig A, Paster W, Asrak O, Dijanovic D, Kellner F, Pickl WF, Huppa JB, Leitner J, Steinberger P. Oncotarget. 2017 May 4;8(39):64892-64906. doi: 10.18632/oncotarget.17615. eCollection 2017 Sep 12. 17615 [pii] PubMed 29029399